Processa Pharmaceuticals, Inc. (PCSA) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and non-oncology drugs. The company operates as a single segment focused on modifying existing FDA-approved oncology drugs to improve safety and efficacy. As of June 30, 2025, the company had 50,349,149 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3,933,918) | $(6,768,323) | $(5,736,707) |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.55) | $(2.11) |
| Operating Expenses | $3,950,783 | $6,797,773 | $5,891,622 |
| Cash and Cash Equivalents (End of Period) | $6,936,620 | $6,936,620 | $5,571,120 |
| Net Cash Used in Operating Activities (YTD) | N/A | $(5,000,253) | $(5,394,713) |
| Net Cash Provided by Financing Activities (YTD) | N/A | $10,745,548 | $6,259,636 |
| Total Liabilities | $2,074,581 | $2,074,581 | $1,533,118 |
| Accumulated Deficit | $(93,987,522) | $(93,987,522) | $(87,219,199) |
Material Changes vs. Prior Period
- Capital Raising: The company significantly increased its cash position through two public offerings in the first half of 2025. In January, it raised net proceeds of $4.4 million, and in June, it raised net proceeds of $6.2 million. Additionally, all pre-funded warrants from these offerings were exercised during the period.
- Expense Growth: Research and development (R&D) expenses increased by approximately $766,000 year-over-year for the six-month period, driven by increased costs for Phase 1B and Phase 2 clinical trials for NGC-Cap. General and administrative (G&A) expenses increased by approximately $140,000, primarily due to salary increases for C-suite executives and higher stock-based compensation.
- Share Count: The weighted average shares outstanding increased significantly due to the public offerings, diluting the per-share loss impact compared to the prior year (loss per share improved from $(2.11) to $(0.55) YTD).
- Liquidity: Cash and cash equivalents grew from $1.2 million at year-end 2024 to $6.9 million at June 30, 2025.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that while current cash plus $2.4 million in gross proceeds received in August 2025 will satisfy capital needs into the first quarter of 2026, there is substantial doubt about the company's ability to continue as a going concern for one year or more without additional funding. The company expects to remain dependent on equity or debt financing.
- Pipeline Updates:
- NGC-Cap: Phase 2 trial for advanced/metastatic breast cancer is actively enrolling patients.
- PCS12852: Entered a binding term sheet with Intact Therapeutics for an exclusive license option. Potential upside includes a $2.5 million payment, 3.5% equity in Intact, and royalties. A related agreement with Yuhan Corporation extended clinical trial deadlines.
- NGC-Gem: Terminated the licensing agreement with Ocuphire Pharma (Opus Genetics) in June 2025.
- Legal Proceedings: The company is defending against a lawsuit filed by Elion regarding a license agreement termination and a fraud lawsuit filed by two investors from a 2021 private offering.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq regarding the minimum $1.00 bid price requirement. It has until August 4, 2025, to regain compliance, though Nasdaq will review the 10-Q before making a final determination on an extension.
- Strategic Shift: Following August 2025 investments, the company is exploring options to pursue a cryptocurrency treasury strategy.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting risk and whether the company has regained compliance with the $1.00 minimum bid price requirement.
- Confirm the execution of the license agreement with Intact Therapeutics for PCS12852, as the term sheet is subject to due diligence and is not yet a binding license.
- Monitor the going concern warning and the company's ability to secure additional financing before Q1 2026 to avoid operational suspension.
- Review the progress of the NGC-Cap Phase 2 trial and the impact of the terminated NGC-Gem license on the overall pipeline strategy.
- Assess the potential impact of the cryptocurrency treasury strategy on the company's balance sheet and risk profile.